Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
49 Cards in this Set
- Front
- Back
|
Rate of fetal mortality in the US
|
6.60%
|
|
|
US Rank in the world in terms of fetal mortality
|
27th
|
|
|
Days after conception that human organogenesis occurs
|
17-56 days
|
|
|
Risk of congenital malformations in fetus of diabetic mother
|
3-4x increased
|
|
|
Dose of folic acid for neural tube defect prevention in general population
|
0.4mg
|
|
|
Percentage of pregnancies that are unintended
|
57%
|
|
|
Percentage of pregnancies that end in abortion
|
25%
|
|
|
Percentage of cardiac output going to placenta
|
50%
|
|
|
Risk of pregnancy per act of intercourse midcycle
|
17-30%
|
|
|
Failure rate of oral contraceptives with perfect to typical use
|
0.3-8%
|
|
|
Failure rate of Mirena IUD
|
0.10%
|
|
|
Typical number of days in the luteal phase
|
14
|
|
|
Mean number of days in human menstrual cycle
|
28
|
|
|
Average number of eggs a woman ovulates in a lifetimes
|
<500
|
|
|
Percentage of married couples who are satisfied with their sex lives
|
87%
|
|
|
Prevalence of erectile dysfunction in men ages 18-59
|
31%
|
|
|
Percentage of women in the community affected by urinary incontinence
|
30%
|
|
|
Percentage of urinary incontinence that can be significantly cured
|
80%
|
|
|
Mortality from necrotizing fasciitis
|
30-50%
|
|
|
High risk HPV (causes cervical cancer)
|
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58
|
|
|
Low risk HPV types
|
6, 11, 42, 43, 44
|
|
|
Stage when most ovarian cancers (40%) are diagnosed
|
Stage III
|
|
|
Average age of menopause
|
51
|
|
|
Term pregnancy
|
37-40 weeks
|
|
|
Preterm pregnancy
|
20-36 weeks
|
|
|
Incidence of PCO in general population
|
3.5-7%
|
|
|
Increased breast cancer risk in patients with nonproliferative breast lesions and non-significant family history
|
none
|
|
|
Increased breast cancer risk in patients with proliferative lesions without atypia
|
1.5-2.0x’s
|
|
|
Increased breast cancer risk in patients with proliferative lesions with atypia
|
4-6x’s
|
|
|
Increased breast cancer risk in patients with carcinoma in situ
|
8-10x’s
|
|
|
General population risk of breast cancer by age 85
|
12.5% or 1 in 8
|
|
|
Breast cancer mortality in the US
|
27/100,000
|
|
|
Reduction in breast CA mortality in women ages 50-69 who are regularly screened
|
30%
|
|
|
Lifetime risk of breast cancer in patients with BRCA1 mutation
|
85%
|
|
|
Lifetime risk of breast cancer in patients with BRCA2 mutation
|
30-40%
|
|
|
Recall rate for further imaging after mammogram screening
|
9.40%
|
|
|
Sensitivity of general population screening mammogram in the US
|
65-75%
|
|
|
Specificity of general population screening mammogram in the US
|
90%
|
|
|
PPV for cancer of general population screening mammogram in the US (percentage of positive screening that have cancer diagnosed)
|
4.80%
|
|
|
Sensitivity of high risk population screening mammogram in the US
|
45%
|
|
|
Specificity of high risk population screening mammogram in the US
|
90%
|
|
|
Sensitivity of high risk population screening breast MRI in the US
|
71%
|
|
|
Specificity of high risk population screening breast MRI in the US
|
90%
|
|
|
Percentage of uterine cancer presenting in stage I
|
72%
|
|
|
Overall 5 year survival of endometrial cancer
|
73%
|
|
|
Ovarian cancer lifetime risk
|
1 in 60 to 1 in 70
|
|
|
Percentage of ovarian cancers occurring in women with genetic predisposition
|
5-10%
|
|
|
Percentage reduction in ovarian cancer with OCP use for 6 years
|
50%
|
|
|
Percentage reduction in endometrial cancer with OCP use for 4 years
|
60%
|
